Why the study?
Does a single oral dose of human-bovine reassortant rotavirus vaccines demonstrate safety and immunogenicity in adults, children, and infants?
Does a single oral dose of human-bovine reassortant rotavirus vaccines demonstrate safety and immunogenicity in adults, children, and infants?
Human-bovine reassortant rotavirus vaccines Wa x UK and Wa x (DS-1 x UK) are well-tolerated and immunogenic in infants, supporting their further evaluation as vaccine candidates.
Supports single-dose oral rotavirus vaccination in young infants; extends reassortant candidate data toward larger efficacy trials.
The safety, infectivity, and immunogenicity of two human-bovine reassortant rotavirus candidate vaccines were evaluated in adults, children, and infants. One of these, Wa x UK, contained a single human rotavirus gene from the Wa strain that encoded VP4 P1A specificity in a background of 10 bovine genes including the VP7 gene that encodes G6 specificity, whereas the other, Wa x (DS-1 x UK), possessed the human rotavirus VP4 gene from the Wa strain as well as the human VP7 gene from strain DS-1 that encoded G2 specificity. Each of these vaccines appeared to be well-tolerated and immunogenic in infants less than 6 months of age following a single oral dose, and therefore should be evaluated further as vaccine candidates.
No takes yet. Share an insight, caveat, or question.
Eichelberger et al. (2002) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: